CALR and neoplasm: Once the “eat me” signals, such as calreticulin (CRT), are exposed on the surfaces of immunogenically dying tumor cells, they promote phagocytosis and presentation of tumor antigens by dendritic cells (DCs) in the context of major histocompatibility complex (MHC) class I or II, triggering antigen-specific T cell responses12,13.